Top-News
Mittwoch,
25.10.2017 08:25
von
PR Newswire
| Aufrufe: 16
Alligator Bioscience AB Interim Report January-September 2017
Tageszeitungen (Symbolbild).
pixabay.com
PR Newswire
STOCKHOLM, Oct. 25, 2017
STOCKHOLM, Oct. 25, 2017 /PRNewswire/ --
Three important collaborations in place. Results in November from ADC-1013 clinical phase I study.
Significant events, July-September
• Aptevo Therapeutics and Alligator Bioscience signed a co-development agreement on the bispecific antibody ALG.APV-527. Preclinical development and initial production activities for clinical trial materials for ALG.APV-527 commenced.
• The immuno-oncology collaboration with Stanford University was expanded. The aim is to predict the clinical efficacy of Alligator's pipeline candidates using biomarkers.
• A research contract was signed with Professor Ignacio Melero, MD, PhD, from the University of Navarra in Spain, for 4-1BB as a target molecule in immunotherapy and cancer therapy.
• The results of the Alligator-led Phase I clinical trial for ADC-1013/JNJ-64457107 will be presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November.
• Janssen's Phase I clinical trial for ADC-1013/JNJ-64457107 is ongoing with approximately 50 patients recruited to date.
Events after the end of the period
Alligator and collaboration partner Aptevo Therapeutics announced on 24 October that the tumor antigen 5T4, associated with many forms of solid tumors, is the second target for ALG.APV-527.
Financial summary
July-September
• Net sales, SEK 1.8 million (4.7).
• Operating loss, SEK 24.5 million (loss: 9.1).
• Loss for the period, SEK 25.8 million (loss: 7.5).
• Loss per share, SEK 0.36 (loss: 0.13).
• Cash and cash equivalents incl. bonds, SEK 588 million (659).
January-September
• Net sales, SEK 5.6 million (51.8).
• Operating loss, SEK 73.0 million (loss: 34.0)
• Loss for the period, SEK 76.3 million (loss: 29.0)
• Loss per share, SEK 1.07 (loss: 0.49)
• Cash flow for the period was a negative SEK 141.5 million (neg: 23.8), of which SEK 74.5 million was invested in corporate bonds.
• During the period, 1,275,000 warrants (230,000) were exercised for an equivalent number of shares.
| Financial summary (Group) | 2017 | 2016 | 2017 | 2016 | 2016 |
| |
Jul-Sep |
Jul-Sep |
Jan-Sep |
Jan-Sep | Jan-Dec |
|
Net sales, TSEK |
1,770 |
4,661 |
5,576 |
51,808 |
58,240 |
|
Operating profit/loss, TSEK |
-24,459 |
-9,133 |
-73,032 |
-33,952 |
-56,082 |
|
Profit/loss for the period, TSEK |
-25,772 |
-7,545 |
-76,274 |
-29,008 |
-48,356 |
|
Cash flow for the period, TSEK |
-25,409 |
-17,780 |
-141,479 |
-23,759 |
287,135 |
|
Cash and cash equivalents including bonds, TSEK |
587,578 |
346,457 |
513,220 |
346,457 |
659,136 |
|
Equity ratio, % |
97% |
97% |
97% Werbung Mehr Nachrichten zur ALLIGATOR BIOSC. AB O.N. Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News |
